Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Brainstorm Cell Therapeutics Inc. (BCLI) had Debt to Equity Ratio of -0.12 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-2.13M |
|
-- |
|
-- |
|
$2.05M |
|
$-2.05M |
|
$-0.08M |
|
$-2.13M |
|
$-2.13M |
|
$-2.13M |
|
$-2.13M |
|
$-2.13M |
|
$-2.13M |
|
$-2.05M |
|
$-2.01M |
|
11.04M |
|
11.04M |
|
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$0.18M |
|
$0.20M |
|
$0.57M |
|
$0.76M |
|
$11.76M |
|
-- |
|
-- |
|
$11.76M |
|
$-11.01M |
|
$-11.01M |
|
$-11.01M |
|
11.04M |
|
| Cash Flow Statement Financials | |
$-1.32M |
|
$0.00M |
|
$1.25M |
|
$0.28M |
|
$0.21M |
|
$-0.07M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.02 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
-0.12 |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.32M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
19.32% |
|
19.32% |
|
-281.72% |
|
19.32% |
|
$-1.00 |
|
$-0.12 |
|
$-0.12 |
|